Skip to main content
Erschienen in: Der Internist 7/2016

10.06.2016 | Computertomografie | Schwerpunkt: Metabolische Knochen- und Gelenkerkrankungen

Hyperurikämie und Gicht

Neues zu einer alten Krankheit

verfasst von: Dr. med. M. Witt, H. Schulze-Koops

Erschienen in: Die Innere Medizin | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Gichtarthritis zählt zu den häufigsten entzündlichen Gelenkerkrankungen. Aufgrund eines zunehmenden Lebensalters und steigenden Lebensstandards ist mit einer Zunahme der Inzidenz und Prävalenz zu rechnen. Durch die Assoziation mit Erkrankungen des metabolischen Syndroms sowie mit kardiovaskulären Erkrankungen geht die Gicht oft mit einer erheblichen Krankheitslast einher. Neben konventionellen Therapeutika stehen für die Harnsäuresenkung und Anfallstherapie neue Medikamente zur Verfügung, auch für komplexe oder therapierefraktäre Patienten.
Literatur
1.
Zurück zum Zitat Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67:960–966CrossRefPubMed Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67:960–966CrossRefPubMed
2.
Zurück zum Zitat Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L (2014) The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73:1470–1476CrossRefPubMed Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L (2014) The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73:1470–1476CrossRefPubMed
3.
Zurück zum Zitat Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, Durme C van, Echteld I van, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewe RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Muller-Ladner U, Ostergaard M, Zochling J, Falzon L, Heijde DM van der (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328–335CrossRefPubMed Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, Durme C van, Echteld I van, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewe RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Muller-Ladner U, Ostergaard M, Zochling J, Falzon L, Heijde DM van der (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328–335CrossRefPubMed
4.
5.
Zurück zum Zitat Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henriquez P, Hernandez-Diaz C, Vargas A, Hofmann F, Gutierrez M (2011) Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther 13:R4CrossRefPubMedPubMedCentral Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henriquez P, Hernandez-Diaz C, Vargas A, Hofmann F, Gutierrez M (2011) Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther 13:R4CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Naredo E, Uson J, Jimenez-Palop M, Martinez A, Vicente E, Brito E, Rodriguez A, Cornejo FJ, Castaneda S, Martinez MJ, Sanz J, Moller I, Batlle-Gualda E, Garrido J, Pascual E (2014) Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73:1522–1528CrossRefPubMed Naredo E, Uson J, Jimenez-Palop M, Martinez A, Vicente E, Brito E, Rodriguez A, Cornejo FJ, Castaneda S, Martinez MJ, Sanz J, Moller I, Batlle-Gualda E, Garrido J, Pascual E (2014) Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73:1522–1528CrossRefPubMed
7.
Zurück zum Zitat Johnson TR, Weckbach S, Kellner H, Reiser MF, Becker CR (2007) Clinical image: Dual-energy computed tomographic molecular imaging of gout. Arthritis Rheum 56:2809CrossRefPubMed Johnson TR, Weckbach S, Kellner H, Reiser MF, Becker CR (2007) Clinical image: Dual-energy computed tomographic molecular imaging of gout. Arthritis Rheum 56:2809CrossRefPubMed
8.
Zurück zum Zitat Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, Schumacher HR, Dalbeth N (2015) Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis 74:1868–1874CrossRefPubMed Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, Schumacher HR, Dalbeth N (2015) Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis 74:1868–1874CrossRefPubMed
9.
Zurück zum Zitat McQueen FM, Doyle A, Dalbeth N (2014) Imaging in the crystal arthropathies. Rheum Dis Clin North Am 40:231–249CrossRefPubMed McQueen FM, Doyle A, Dalbeth N (2014) Imaging in the crystal arthropathies. Rheum Dis Clin North Am 40:231–249CrossRefPubMed
10.
Zurück zum Zitat Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liote F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ (2015) 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74:1789–1798CrossRefPubMedPubMedCentral Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liote F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ (2015) 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74:1789–1798CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446CrossRef Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446CrossRef
12.
Zurück zum Zitat Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64:1447–1461CrossRef Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 64:1447–1461CrossRef
13.
Zurück zum Zitat Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62:1060–1068CrossRefPubMed Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62:1060–1068CrossRefPubMed
14.
Zurück zum Zitat Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13CrossRefPubMed Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13CrossRefPubMed
15.
Zurück zum Zitat Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology 52:127–134CrossRefPubMed Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology 52:127–134CrossRefPubMed
16.
Zurück zum Zitat Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31:2429–2432PubMed Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31:2429–2432PubMed
17.
Zurück zum Zitat Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:2529–2536CrossRefPubMed Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:2529–2536CrossRefPubMed
18.
Zurück zum Zitat Becker MA, Schumacher HR Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461CrossRefPubMed Becker MA, Schumacher HR Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461CrossRefPubMed
19.
Zurück zum Zitat Schett G, Dayer JM, Manger B (2016) Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 12:14–24CrossRefPubMed Schett G, Dayer JM, Manger B (2016) Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 12:14–24CrossRefPubMed
20.
Zurück zum Zitat Schlesinger N (2011) Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 71:1413–1439CrossRefPubMed Schlesinger N (2011) Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 71:1413–1439CrossRefPubMed
22.
Zurück zum Zitat Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839–1848CrossRefPubMed Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839–1848CrossRefPubMed
23.
Zurück zum Zitat Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264–1271CrossRefPubMedPubMedCentral Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264–1271CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H (2012) Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16:89–95CrossRefPubMed Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H (2012) Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol 16:89–95CrossRefPubMed
25.
Zurück zum Zitat Diaz-Torne C, Perez-Herrero N, Perez-Ruiz F (2015) New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 27:164–169CrossRefPubMed Diaz-Torne C, Perez-Herrero N, Perez-Ruiz F (2015) New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 27:164–169CrossRefPubMed
26.
Zurück zum Zitat Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-207919PubMedCentral Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-207919PubMedCentral
27.
Zurück zum Zitat Kratzer JT, Lanaspa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, Ortlund EA, Johnson RJ, Gaucher EA (2014) Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 111:3763–3768CrossRefPubMedPubMedCentral Kratzer JT, Lanaspa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, Ortlund EA, Johnson RJ, Gaucher EA (2014) Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 111:3763–3768CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306:711–720CrossRefPubMed Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306:711–720CrossRefPubMed
29.
Zurück zum Zitat Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA (2013) Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 15:R137CrossRefPubMedPubMedCentral Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA (2013) Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 15:R137CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, Boudes PF (2016) A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. doi:10.1002/art.39684 [Epub ahead of print]PubMed Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, Boudes PF (2016) A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. doi:10.1002/art.39684 [Epub ahead of print]PubMed
Metadaten
Titel
Hyperurikämie und Gicht
Neues zu einer alten Krankheit
verfasst von
Dr. med. M. Witt
H. Schulze-Koops
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Innere Medizin / Ausgabe 7/2016
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-016-0083-1

Weitere Artikel der Ausgabe 7/2016

Der Internist 7/2016 Zur Ausgabe

Schwerpunkt: Metabolische Knochen- und Gelenkerkrankungen

Individualisierte Therapie der Osteoporose

Mitteilungen des BDI - Kongresse

Mitteilungen des BDI - Kongresse

Einführung zum Thema

Osteologie 2016

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.